Conference Correspondent

As patients with multiple myeloma are now living longer, survivorship care is becoming more crucial.
Leslie Lauersdorf addresses the challenges associated with staying abreast of the side effects, management, and sequencing for new multiple myeloma treatments.
Leslie Lauersdorf discusses the need to balance optimism and realism in caring for patients with relapsed/refractory multiple myeloma.
Leslie Lauersdorf insist that it's vital to inform your patients about what's involved in beginning daratumumab treatments, especially because of the lengthy chair time.
Leslie Lauersdorf believes patient education is important in both newly diagnosed pateints with multiple myeloma or patients with relapsed/refractory disease to help them understand their disease and the different treatment options.
Leslie Lauersdorf notes that having patients assist in managing their own side effects is important to help them stay on treatment and improve their quality of life.
Leslie Lauersdorf is excited by the prospect of new mutliple myeloma therapies, and notes that finding the best sequence for each patient is key.
Leslie Lauersdorf hopes that multiple myeloma can eventually become a chronic disease, if not cured completely, so that patients with the disease can live life uninterrupted.
Tiffany Richards identifies the many recources she leverages to stay current on new treatments.
Tiffany Richards explains the difficulties she has encountered in managing patients who have battled myeloma for an extended period of time and have experienced multiple relapses.
Page 2 of 11
Results 11 - 20 of 101